SynthesisEuropean urology2012
Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology.
Synthesis in European urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A systematic investigation of clear cell renal cell carcinoma using meta-analysis and systems biology approaches.Molecular genetics and genomics : MGG · 2024Pooled it
- Meta-analysis of gene expression and integrin-associated signaling pathways in papillary renal cell carcinoma subtypes.Oncotarget · 2016Pooled it
- FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Prognostic significance of systemic immunoinflammatory biomarkers and pathological features in clear cell renal cell carcinoma: a multicenter study.Annals of medicine · 2026Trial
- Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma.Future oncology (London, England) · 2020Trial
- Article
- First-Line Treatment Strategies in IMDC Favourable-Risk Metastatic Clear Cell Renal Cell Carcinoma.Oncology research · 2026Review
- One size does not fit all: rethinking IO-TKI use in favorable-risk metastatic ccRCC.Frontiers in oncology · 2026Article
- Prognostic impact of nephrectomy and a prediction model for estimating the survival benefit of nephrectomy for patients with clear cell renal cell carcinoma (ccRCC).Translational andrology and urology · 2025Article
- Sex differences in cancer incidence: prospective analyses in the UK Biobank.British journal of cancer · 2025Article
- Examining the evolving landscape of kidney cancer mortality in the United States.The oncologist · 2025Article
- Biomarker-informed care for patients with renal cell carcinoma.Nature cancer · 2025Review
- Identification of kidney cell types in scRNA-seq and snRNA-seq data using machine learning algorithms.Heliyon · 2024Article
- Prognostic factors and prognostic model of non-metastatic clear cell renal cell carcinoma.BMC cancer · 2024Article
- Sex-specific survival gene mutations are discovered as clinical predictors of clear cell renal cell carcinoma.Scientific reports · 2024Article
- The potential of organoids in renal cell carcinoma research.BMC urology · 2024Review
- Diagnostic, predictive and prognostic molecular biomarkers in clear cell renal cell carcinoma: A retrospective study.Cancer reports (Hoboken, N.J.) · 2024Review
- Review
- Tumor microenvironment-based signatures distinguish intratumoral heterogeneity, prognosis, and immunogenomic features of clear cell renal cell carcinoma.Journal of the National Cancer Center · 2023Article
- Molecular differences in renal cell carcinoma between males and females.World journal of urology · 2023Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) displays molecular and histologic heterogeneity. Previously described subsets of this disease, ccA and ccB, were defined based on multigene expression profiles, but it is unclear whether these subgroupings reflect the full spectrum of disease or how these molecular subtypes relate to histologic descriptions or gender.
objectiveDetermine whether additional subtypes of ccRCC exist and whether these subtypes are related to von Hippel-Lindau (VHL) inactivation, hypoxia-inducible factor (HIF) 1 and 2 expression, tumor histology, or gender. DESIGN, SETTING, AND
participantsSix large, publicly available ccRCC gene expression databases were identified that cumulatively provided data for 480 tumors for meta-analysis via meta-array compilation. MEASUREMENTS: Unsupervised consensus clustering was performed on the meta-arrays. Tumors were examined for the relationship of multigene-defined consensus subtypes and expression signatures of VHL mutation and HIF status, tumor histology, and gender. RESULTS AND LIMITATIONS: Two dominant subsets of ccRCC were observed. However, a minor third cluster was revealed that correlated strongly with a wild type (WT) VHL expression profile and indications of variant histologies. When variant histologies were removed, ccA tumors naturally divided by gender. This technique is limited by the potential for persistent batch effect, tumor sampling bias, and restrictions of annotated information.
conclusionsThe ccA and ccB subsets of ccRCC are robust in meta-analysis among histologically conventional ccRCC tumors. A third group of tumors was identified that may represent a new variant of ccRCC. Within definitively clear cell tumors, gender may delineate tumors in such a way that it could have implications regarding current treatments and future drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.